N/A N=101 Prostatic Urethral Lift in Subject With Acute Urinary Retention
Acute Urinary Retention · Benign Prostatic Hyperplasia
Primary: Successful Trial Without Catheter Peri-procedurally — 29; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=84 Urinary Retention After Total Laparoscopic Hysterectomy With Immediate Foley Catheter Removal Versus Backfill Void Trial
Urinary Retention · Voiding Disorders
Primary: Number of Participants With Void Trial Failure Rate — 7; 11 Participants
N/A N=84 Treatment for Acute Postoperative Voiding Dysfunction
Urinary Retention
Primary: Persistent Retention — 29; 21 participants
Phase 3 N=179 Effect of Preoperative Tamsulosin on Postoperative Urinary Retention
Postoperative Retention of Urine
Primary: Number of Participants With Postoperative Urinary Retention — 14; 16 Participants
Phase 3 N=151 Prevention of Post-operative Urinary Retention
Urinary Retention · Urinary Tract Infections
Primary: Need for Any Intermittent Catheterization Postoperatively as a Binary Outcome — 18; 22 Participants
N/A N=491 Urinary Retention After Laparoscopic Inguinal Hernia Repair: Comparing the Use of the Intraoperative Urinary Catheter
Inguinal Hernia
Primary: Number of Participants With Post Operative Urinary Retention — 23; 21 Participants
Phase 4 N=150 The Impact of Retropubic Lidocaine vs Saline on Postoperative Urinary Retention Following Midurethral Sling
Stress Urinary Incontinence
Primary: Number of Subjects With Urinary Retention — 15; 14 Participants
Phase 3 N=132 Tamsulosin vs Placebo to Prevent Postoperative Urinary Retention in Female Pelvic Reconstructive Surgery
Urinary Retention · Lower Urinary Tract Symptoms · Stress Urinary Incontinence
Primary: Postoperative Urinary Retention — 16; 5 Participants
Phase 3 N=20 Effect of Tizanidine on Postoperative Urinary Retention After Sacrospinous Suspension
Postoperative Urinary Retention · Sacrospinous Vaginal Vault Suspension · Reconstructive Pelvic Surgery
Primary: Number of Participants With Postoperative Urinary Retention — 11 Participants
Phase 4 N=395 Antimuscarinics as the First-line Treatment for Male With IPSS-V/S≤1
Bladder Outlet Obstruction
Primary: The Global Response Assessment (GRA) After the Treatment Day — 89; 218; 27; 61 participants
N/A N=8,617 Evaluating the Impact of Early Versus Delayed 5 Alpha Reductase Inhibitor Treatment on the Risk of Emergent Surgery in Men With Benign Prostatic Hyperplasia
Prostatic Hyperplasia
Primary: Number of Participants Who Experienced Progression of Disease — 589; 393; 280; 212 participants — p=0.002
N/A N=388 RCT Foley Catheter Study for Elective TJA
Postoperative Urinary Retention · Total Hip Arthroplasty · Total Knee Arthroplasty
Primary: Number of Patients Who Developed Postoperative Urinary Retention (POUR), Unable to Void a Volume Greater Than or Equal to 30ml/hr — 4; 5 Participants
Phase 4 N=154 Nitrofurantoin Prophylaxis During Catheter-managed Acute Urinary Retention After Pelvic Reconstructive Surgery
Pelvic Organ Prolapse
Primary: Number of Participants Experiencing Urinary Tract Infection Within 6 Weeks of Surgery — 13; 13 Participants — p=0.97
N/A N=158 Self-discontinuation of a Transurethral Catheter
Postoperative Urinary Retention
Primary: Number of Participants With Postoperative Urinary Retention — 11; 11 Participants — p=0.5
N/A N=104 Spontaneous Void Requirements for Patients Undergoing Ambulatory Anorectal Surgery
Complications, Postoperative
Primary: PACU Time — 129.1; 210.0 Minutes
Phase 4 N=232 The Long Term Effects of Alfuzosin(Xatral XL) in Lower Urinary Tract Symptoms(LUTS)/BPH Patients
BPH
Primary: Primary Outcome; International Prostate Symptom Score Changes Between 4 Groups Compared to Baseline After 12 mo Treatment — 13.0; 12.0; 10.6; 13.4 score — p=<0.05
N/A N=142 Optimal Duration of Indwelling Urinary Catheter Following Pelvic Surgery
Urinary Retention
Primary: Number of Participants With Acute Urinary Retention — 6; 7 Participants
Phase 4 N=23 Treatment of Incontinence Without Memory Problems
Urge Incontinence · Urinary Incontinence, Urge
Primary: The Number of Participants Who Completed and Discontinued the Study — 11; 10; 1; 1 Participants — p=0.949
N/A N=21 Efficacy of Botulinum Toxin Type A for the Treatment of Non-neurogenic Urinary Urge Incontinence
Urinary Urge Incontinence
Primary: Change in Maximum Capacity at Cystoscopy Between Baseline and 6 Month Follow-up — -97.5; 64.1 mL — p=.016
Phase 3 N=152 Effect of Phenazopyridine on Prolapse Surgery Voiding Trials
Urinary Retention Postoperative
Primary: Number of Participants With Postoperative Urinary Retention After Pelvic Organ Prolapse Surgery (INTENT-TO-TREAT) — 30; 25 Participants
Phase 4 N=46 Dutasteride With Tolterodine ER or Placebo to Treat Lower Urinary Tract Symptoms (LUTS)
Benign Prostatic Hyperplasia (BPH)
Primary: Post-void Residual (PVR) Volume — 101.7; 75.8 mL
Phase 4 N=84 Mirabegron and Urinary Urgency Incontinence
Overactive Bladder
Primary: Response to Therapy — 15; 29 Participants
Phase 3 N=171 The POUR (Postoperative Urinary Retention) Study
Postoperative Urinary Retention
Primary: Number of Participants With Urinary Retention — 0; 11; 74; 63 Participants
Phase 4 N=50 Postoperative Urinary Retention in Patients After Noncardiac Surgery and Reversal of Neuromuscular Block
Neuromuscular Blockade
Primary: Urine Residual in PACU — 219; 222 ml
Phase 4 N=98 Assessing Pyridium for Post-Sling Urinary Retention
Urinary Retention
Primary: Number of Participants Considered to Have Passed Their Voiding Trial — 30; 30 Participants
Phase 2 N=80 URO-902 in Female Subjects With Overactive Bladder and Urge Urinary Incontinence
Overactive Bladder With Urge Urinary Incontinence
Primary: Change From Baseline at Week 12 in Average Daily Number of Urgency Episodes — -1.13; -2.43; -3.37 Urgency episodes per day — p==0.1722
Phase 4 N=20 Inflammation in Women With Urgency Urinary Incontinence Treated With Anticholinergics
Urinary Incontinence · Urgency Urinary
Primary: Inflammatory Markers in Urine Will be Measured Using Immunoenzyme Assays to Measure the Interaction of Anticholinergic Treatment and the Inflammatory Milieu. — 2.192…
Phase 3 N=249 Anticholinergic vs. Botox Comparison Study
Urge Urinary Incontinence · Overactive Bladder
Primary: Change in Urge Urinary Incontinence (UUI) Episodes — -3.13; -3.15; -3.32; -3.25 Mean change in UUI episodes from baselin
N/A N=115 Artificial Urinary Sphincter Clinical Outcomes
Stress Urinary Incontinence
Primary: Number of Subjects With Reduction in 24 Hour Pad Weight Test at 12 Months — 91 Participants — p=< 0.001
Phase 4 N=181 Treatment of Symptoms After Stent Placement for Urinary Tract Obstruction
Ureteral Obstruction
Primary: Ureteral Stent Symptom Questionnaire Score Up to 24 Hours Prior to Stent Insertion — 1.76; 1.84; 2.02; 1.93 score on a scale